权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Broadly Effective HCV Vaccine

广泛有效的 HCV 疫苗

基本信息

批准号：
10557871
负责人：
Mansun Law
金额：
$ 208.35万
依托单位：
SCRIPPS RESEARCH INSTITUTE, THE
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-02-01 至 2027-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10557871
关键词：
Animal Model Animals Antibodies Antibody Response Antibody Specificity Antigen Presentation Antigens Antiviral Agents Autoimmune B-Lymphocytes Binding Sites Biochemical Biological Assay CD81 gene Case Study Communication Complex Computer Models Cost efficiency Electron Microscopy Electrons Engineering Epidemic Epitope Mapping Epitopes Face Future Generations Genes Genetic Genetic Variation Genotype Glycoproteins Goals Hepatitis C Hepatitis C Vaccine Hepatitis C virus Human Human Volunteers Immune Immune response Immune system Immunization Immunize Infection Knowledge Laboratories Liver Cirrhosis Macaca Macaca mulatta Malignant neoplasm of liver Maps Microscopic Modeling Mutagenesis Population Production Program Research Project Grants Reagent Recombinants Reproducibility Research Research Project Grants Resolution Resources Role Scanning Site Standardization Structure Vaccinated Vaccination Vaccine Antigen Vaccine Design Vaccines Viral Viral Envelope Proteins Virus Visual animal resource biophysical properties immunogenicity improved innovation interdisciplinary approach mouse model nanoparticle neutralizing antibody nonhuman primate novel polyclonal antibody pre-clinical preclinical evaluation programs rational design receptor receptor binding research clinical testing self assembly single molecule spatial relationship success synergism vaccine candidate vaccine development vaccine immunogenicity viral transmission virology virus envelope

项目摘要

Program Summary The overarching goal of this P01 proposal is to develop novel hepatitis C virus (HCV) vaccine candidates that can elicit potent broadly neutralizing antibody responses in immunization. Despite highly effective antiviral drugs against HCV now being available, the continuous increase in new infections underscores the real-world challenges in combating this human infection without a vaccine. This P01 proposal “Broadly Effective Hepatitis C Vaccine” is built on the hypothesis that an HCV vaccine effective against diverse circulating HCV strains can be developed through rational engineering of vaccines to enhance antigen immunogenicity and presentation of conserved neutralizing epitopes, and to target well-defined multidonor class broadly neutralizing antibody (bnAb) responses to HCV. Multidonor class antibody responses are antibodies sharing common genetic and functional features produced in infection or vaccination at the population level. This P01 program consists of 2 research projects, supported by an admin core and 2 scientific cores. The overall aims of the program are: (1) To determine the structures of HCV envelope glycoproteins important for rational vaccine design; (2) To rationally design HCV vaccine antigens for elicitation of broadly neutralizing antibodies that will be effective against diverse circulating viral strains; (3) To determine the antibody responses elicited by HCV vaccine antigens in preclinical animal models. Success in this research program will result in both basic scientific knowledge and a strong HCV vaccine candidate for future pilot production and clinical testing.

项目总结